Ajax Therapeutics Inc

📅 Upcoming

🕒 Recent(90d)

News

• Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
  Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup…
  biopharma_dive · 20d ago
• Schrödinger births new immunology and inflammation biotech, Tectora Therapeutics
  Schrödinger announced the launch of new immune disease-focused Tectora Therapeutics, which comes online with a $55 million series A financing round.
  fiercebiotech · 23d ago
• Lilly confident in slow and steady Foundayo launch, as ex-US sales shine
  Foundayo clocked $98 million in sales in Q2, the first quarter it was available, compared to Novo’s $355 million for the same sales period.
  biospace · 1mo ago
• Lilly scores early positive data for new JAK drug
  Acquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.
  biopharma_dive · 3mo ago
• Lilly to buy startup Ajax in bid for a better JAK drug
  Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.
  biopharma_dive · 5mo ago
• STAT+: Astellas retries XLMTM gene therapy after deaths
  Veradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech news
  stat · 5mo ago
• Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor
  Eli Lilly keeps putting its GLP-1 windfall to use. On Monday, the anti-obesity drugmaker announced its latest deal to expand its pipeline of future drugs, saying it would spend as much as
  endpoints · 5mo ago